Novavax, Inc. faces declining revenues and high risks despite the Sanofi deal and cost-cutting measures. Click here for my ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced that it has filed for authorization with Health Canada for its 2024-2025 ...

The price of bitcoin fell below $90,000 and other cryptocurrencies saw large drops Tuesday morning, erasing some of the gains ...

The growing global prevalence of influenza, mainly due to the transmission of the virus through droplets from coughing and sneezing, is the primary driver for the need for influenza vaccination.

Novavax sees royalties ... between the U.S. and China after President Donald Trump delayed tariffs for Canada and Mexico. February 4, 2025 Kennedy's promises on vaccines secure senior Republican ...

Today in History for Feb. 17: ...

Novavax Inc. closed 67.02% below its 52-week high of $23.86, which the company achieved on June 6th.

The company has struggled to keep up with the pace of its rivals Moderna and Pfizer, which make messenger RNA-based vaccines ...

Novavax Inc. NVAX) on Thursday reported a loss of $81 million in its fourth quarter.